Alnylam presents new results from the illuminate-c phase 3 study of lumasiran in patients with advanced primary hyperoxaluria type 1

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced new positive results from the six-month primary analysis period of the illuminate-c phase 3 open-label study of lumasiran, an rnai therapeutic targeting hydroxyacid oxidase 1 (hao1) – the gene encoding glycolate oxidase (go) – that is being investigated for the treatment of patients of all ages with advanced primary hyperoxaluria type 1 (ph1). as previously rep
ALNY Ratings Summary
ALNY Quant Ranking